Hypermarcas (OTCMKTS:HYPMY) Sees Large Volume Increase - Here's What Happened

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) shares saw an uptick in trading volume on Wednesday . 429,810 shares traded hands during mid-day trading, an increase of 3,045% from the previous session's volume of 13,666 shares.The stock last traded at $5.07 and had previously closed at $5.02.

Hypermarcas Stock Performance

The stock's 50 day simple moving average is $4.20 and its two-hundred day simple moving average is $3.56. The company has a market capitalization of $3.08 billion, a P/E ratio of 20.23 and a beta of 0.79. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.26 and a quick ratio of 0.80.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The company reported ($0.04) earnings per share for the quarter. Hypermarcas had a net margin of 12.51% and a return on equity of 6.95%. The company had revenue of $184.34 million during the quarter.

Hypermarcas Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.